San Diego Business Journal

Vividion Therapeutics, a biotech company discovering and developing highly selective small molecule medicines that drug traditionally inaccessible targets, recently announced that it has entered into an exclusive worldwide option and license agreement with Roche to leverage its proteomics screening platform and proprietary small molecule library to target novel E3 ligases, as well as a range of oncology and immunology therapeutic targets. Roche has the exclusive right to license resulting compounds at various stages of development, according to Vividion.

San Diego-based Vividion said it will receive $135 million in a cash upfront payment from Roche and is eligible to receive several billion dollars in payments based on the achievement of preclinical, development and commercial milestones, as well as royalties on sales of commercialized products resulting from the collaboration.

“We are thrilled to partner with Roche, marking the second major collaboration for Vividion focused on developing small molecule drugs against promising, untapped therapeutic targets,” said Diego Miralles, chief executive officer of Vividion. “This collaboration with Roche will further expand a new pillar of our pipeline focused on leveraging distinct E3 ligases to bring cutting-edge treatments to patients in need.”